Literature DB >> 6336604

Evidence that a human osteosarcoma cell line which secretes a mitogen similar to platelet-derived growth factor requires growth factors present in platelet-poor plasma.

D T Graves, A J Owen, H N Antoniades.   

Abstract

A human osteosarcoma-derived cell line, 2T, grows almost as well in medium supplemented with platelet-poor plasma (PPP) as it does in medium containing fetal bovine serum. Human diploid fibroblasts, in contrast, will not grow in medium containing PPP unless human platelet-derived growth factor (PDGF) is added. PPP treated with carboxymethyl-Sephadex at pH 7.4 was able to support 2T cell proliferation, although at a reduced rate compared to untreated PPP. Addition of PDGF to carboxymethyl-Sephadex-treated PPP did not restore the growth rate. However, insulin-like growth factor isolated from human plasma did partially restore the activity of carboxy-methyl-Sephadex-treated PPP. Medium conditioned by 2T cells was mitogenic for quiescent BALB/c3T3 cells and human diploid fibroblasts. Antiserum to human PDGF blocked the mitogenic activity of the conditioned medium. Partial characterization confirmed the biochemical similarity to PDGF. The data are consistent with the hypothesis that these osteosarcoma-derived cells have growth factor requirements similar to those of normal mesenchymal cells but are able to overcome the normal growth limitations by autocrine secretion of PDGF-like mitogens.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336604

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Growth regulatory factors and bone.

Authors:  G R Mundy; D Chen; M Zhao; S Dallas; C Xu; S Harris
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein.

Authors:  J Nilsson; M Sjölund; L Palmberg; J Thyberg; C H Heldin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Isolation and sequencing of a cDNA clone homologous to the v-sis oncogene from human endothelial cells.

Authors:  B D Tong; S E Levine; M Jaye; G Ricca; W Drohan; T Maciag; T F Deuel
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

4.  Identification of processing events in the synthesis of platelet-derived growth factor-like proteins by human osteosarcoma cells.

Authors:  D T Graves; A J Owen; S R Williams; H N Antoniades
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 5.  Peptide growth factors and inflammation, tissue repair, and cancer.

Authors:  M B Sporn; A B Roberts
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

6.  A glioma-derived analog to platelet-derived growth factor: demonstration of receptor competing activity and immunological crossreactivity.

Authors:  M Nistér; C H Heldin; A Wasteson; B Westermark
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

Review 7.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents.

Authors:  D F Bowen-Pope; A Vogel; R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.

Authors:  W J Houlihan; M L Lee; P G Munder; G M Nemecek; D A Handley; C M Winslow; J Happy; C Jaeggi
Journal:  Lipids       Date:  1987-11       Impact factor: 1.880

10.  Nucleotide sequence of transforming human c-sis cDNA clones with homology to platelet-derived growth factor.

Authors:  L Ratner; S F Josephs; R Jarrett; M S Reitz; F Wong-Staal
Journal:  Nucleic Acids Res       Date:  1985-07-25       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.